SCWD Publications Digest

Staying informed on the latest in cachexia, sarcopenia, and wasting disorders research is essential yet challenging. The SCWD Digest offers concise updates and expert insights into significant studies and developments. We highlight and link directly to leading research, making it easier for healthcare professionals to access and apply groundbreaking findings. Our goal: empower the medical community to advance patient care worldwide efficiently.

AllAgeingCachexiaCancer CachexiaClinical TrialsExerciseFrailtyFrom the literatureGuidelinesMuscleNutritionOther SCWD EventsSarcopeniaWasting Disorders

Cancer cachexia induces senescent reprogramming of brown adipose tissue and pro-cachectic S100A9 secretion by adipocytes.

Cancer-associated cachexia (CAC) is a multifactorial wasting syndrome characterized by progressive loss of fat and lean mass, systemic inflammation, and poor therapeutic responsiveness. While brown adipose tissue (BAT) is traditionally considered a protective, energy-dissipating organ, its qualitative remodeling in CAC...

📰 Journal: Cell Death & Disease
Read MoreCancer cachexia induces senescent reprogramming of brown adipose tissue and pro-cachectic S100A9 secretion by adipocytes.

Elevated Circulating Ceramides 18:0 and 24:1 as a Risk Factor for Sarcopenia: In Vitro, Animal, and Clinical Evidence.

BACKGROUND

Ceramides have garnered considerable attention as pro-aging bioactive lipids implicated in both metabolic dysfunction and musculoskeletal decline. Among these, C18:0 and C24:1 ceramides may play a role in the pathophysiology of sarcopenia, a key manifestation of age-related deterioration. However, their...

📰 Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MoreElevated Circulating Ceramides 18:0 and 24:1 as a Risk Factor for Sarcopenia: In Vitro, Animal, and Clinical Evidence.

RIPK3 Inhibition Mitigates Denervated Muscle Atrophy via NOX4-Mediated Mitochondrial Restoration and Inflammation Suppression.

BACKGROUND

Peripheral nerve injury-induced muscle atrophy shares core pathophysiological features with systemic wasting disorders including cachexia and sarcopenia, yet early molecular triggers remain undefined. This study investigates the pathogenic role of receptor-interacting protein kinase 3 (RIPK3) in denervation atrophy.

METHODS

Sciatic denervation was...

📰 Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MoreRIPK3 Inhibition Mitigates Denervated Muscle Atrophy via NOX4-Mediated Mitochondrial Restoration and Inflammation Suppression.

Independent validation of the Mosamatic deep learning automated skeletal muscle and adipose tissue segmentation tool in an external Chinese cancer patient cohort.

OBJECTIVES

Deep learning neural network (DLNN)-based tools can automate body composition analysis for cancer cachexia research. We aimed to evaluate a DLNN tool trained on a European population of Chinese cancer patients.

METHODS

Computed tomography (CT) images at the 3rd lumbar vertebral (L3)...

Read MoreIndependent validation of the Mosamatic deep learning automated skeletal muscle and adipose tissue segmentation tool in an external Chinese cancer patient cohort.

Exercise Modalities to Preserve Muscle Mass and Bone Health After Metabolic Bariatric Surgery.

BACKGROUND

Metabolic bariatric surgery (MBS) effectively reduces fat mass (FM), but how to best preserve muscle and bone mass after MBS is unknown.

OBJECTIVE

This study aimed to evaluate the effect of aerobic, resistance and combined exercise regimens on body composition, bone mineral...

📰 Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MoreExercise Modalities to Preserve Muscle Mass and Bone Health After Metabolic Bariatric Surgery.

The pathology and diagnosis of cancer cachexia and a treatment insight from natural products: A review.

Cancer cachexia, which is characterized by weight loss and muscle wasting with or without fat depletion, is a complex syndrome that commonly seen in patients with advanced cancer. The underlying pathophysiological mechanisms of cancer cachexia involve in systemic inflammation, abnormal...

📰 Journal: Biochimica Et Biophysica Acta-Reviews On Cancer
Read MoreThe pathology and diagnosis of cancer cachexia and a treatment insight from natural products: A review.

Muscle Health and Prognosis in Patients With Cancer: New Insights.

BACKGROUND

Reduced muscle mass and impaired composition have each been independently associated with worse outcomes in patients with cancer. However, emerging evidence suggests that reduced muscle strength-namely, dynapenia-may be particularly important for prognostication, as it is easier to assess in clinical...

📰 Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMuscle Health and Prognosis in Patients With Cancer: New Insights.

Deubiquitinase YOD1 Inhibition Suppresses DEX- and Denervation-Induced Muscle Atrophy Through MAFbx Destabilization.

BACKGROUNDS

Muscle atrophy, characterized by progressive loss of muscle mass and function, is driven by muscle-specific E3 ligases MAFbx and MuRF1. While transcriptional regulation of E3 ligases is documented, the mechanism of their regulation by the ubiquitin-proteasome system remains unclear. This...

📰 Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MoreDeubiquitinase YOD1 Inhibition Suppresses DEX- and Denervation-Induced Muscle Atrophy Through MAFbx Destabilization.

Sarcopenia promotes tumorigenesis by disrupting NOTCH-SDC2-regulated biogenesis of muscle-derived extracellular vesicles.

Sarcopenia is an age-related condition characterized by loss of skeletal muscle mass and strength and is associated with increased cancer incidence and mortality, yet how muscle decline promotes tumorigenesis remains unclear. Here, we show that skeletal muscle functions as an...

📰 Journal: Nature Communications
Read MoreSarcopenia promotes tumorigenesis by disrupting NOTCH-SDC2-regulated biogenesis of muscle-derived extracellular vesicles.

Simple clinical parameters to identify sarcopenia 1 year after gastrectomy for gastric cancer.

BACKGROUND

New-onset sarcopenia may develop after gastrectomy even in patients with normal muscle mass, but its detection in routine practice remains challenging. This study evaluated body composition changes after gastrectomy and identified clinical parameters associated with sarcopenia development.

METHODS

This retrospective study included...

📰 Journal: Gastric Cancer
Read MoreSimple clinical parameters to identify sarcopenia 1 year after gastrectomy for gastric cancer.

Systemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology-Specific End-Stage Liver Disease.

BACKGROUND

Patients with end-stage liver disease (ESLD) often present with sarcopenia, defined as loss of skeletal muscle mass and quality, which is associated with reduced quality of life and increased mortality. However, the molecular mechanisms driving sarcopenia in ESLD are not...

📰 Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MoreSystemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology-Specific End-Stage Liver Disease.

Whole Genome Sequence Analysis of Weight Loss in 16 972 Participants With COPD Reveals Novel Risk Loci in DRAIC and RFX3.

BACKGROUND

Chronic obstructive pulmonary disease (COPD) is associated with musculoskeletal comorbidities, including cachexia. Weight loss (WL) is the major criterion for cachexia and increases risk for mortality in COPD. Risk factors for WL in COPD are incompletely understood. We performed this...

📰 Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MoreWhole Genome Sequence Analysis of Weight Loss in 16 972 Participants With COPD Reveals Novel Risk Loci in DRAIC and RFX3.

Cancer IDO1-Mediated Tryptophan-Kynurenine Metabolic Reprogramming to Drive Skeletal Muscle Atrophy and Cachexia Acceleration.

BACKGROUND

Cancer cachexia is a debilitating syndrome characterized by severe skeletal muscle wasting, which significantly impairs patient quality of life and survival. Indoleamine 2,3-dioxygenase 1 (IDO1), a key enzyme in tryptophan (Trp) metabolism, is often upregulated in cancers, but its specific...

📰 Journal: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCancer IDO1-Mediated Tryptophan-Kynurenine Metabolic Reprogramming to Drive Skeletal Muscle Atrophy and Cachexia Acceleration.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!